David J. Bajor

728 total citations · 1 hit paper
15 papers, 491 citations indexed

About

David J. Bajor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David J. Bajor has authored 15 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in David J. Bajor's work include Pancreatic and Hepatic Oncology Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Renal cell carcinoma treatment (3 papers). David J. Bajor is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Renal cell carcinoma treatment (3 papers). David J. Bajor collaborates with scholars based in United States, Australia and France. David J. Bajor's co-authors include Elizabeth L. Buza, James Monslow, Liang‐Chuan S. Wang, Kheng Newick, Cynthia Clendenin, Ellen Puré, Shaun O’Brien, Amy C. Durham, John Scholler and Albert Lo and has published in prestigious journals such as Cancer Research, Annals of Surgery and International Journal of Environmental Research and Public Health.

In The Last Decade

David J. Bajor

14 papers receiving 484 citations

Hit Papers

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
    2015 407 citations Albert Lo, Liang‐Chuan S. Wang et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David J. Bajor United States 6 418 140 131 106 65 15 491
Frank P. Assen Austria 5 210 0.5× 132 0.9× 124 0.9× 76 0.7× 60 0.9× 5 436
Kellie A. Mouchemore Australia 9 282 0.7× 262 1.9× 137 1.0× 90 0.8× 49 0.8× 10 535
Cody E. Cotner United States 4 464 1.1× 183 1.3× 136 1.0× 66 0.6× 127 2.0× 10 537
Huda I. Atiya United States 8 258 0.6× 202 1.4× 175 1.3× 114 1.1× 28 0.4× 11 491
Philippe De La Rochère France 6 206 0.5× 202 1.4× 149 1.1× 77 0.7× 37 0.6× 7 478
Matthew A. Lakins United Kingdom 4 369 0.9× 264 1.9× 153 1.2× 87 0.8× 44 0.7× 9 494
Axel Lechner Germany 12 435 1.0× 328 2.3× 135 1.0× 84 0.8× 36 0.6× 28 660
Dorota E. Kuczek Denmark 4 316 0.8× 233 1.7× 119 0.9× 60 0.6× 110 1.7× 5 517
Priska Auf der Maur Switzerland 5 240 0.6× 174 1.2× 160 1.2× 96 0.9× 50 0.8× 6 412
Wilson Wu United States 5 320 0.8× 105 0.8× 85 0.6× 114 1.1× 41 0.6× 16 393

Countries citing papers authored by David J. Bajor

Since Specialization
Citations

This map shows the geographic impact of David J. Bajor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Bajor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Bajor more than expected).

Fields of papers citing papers by David J. Bajor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Bajor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Bajor. The network helps show where David J. Bajor may publish in the future.

Co-authorship network of co-authors of David J. Bajor

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Bajor. A scholar is included among the top collaborators of David J. Bajor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Bajor. David J. Bajor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Hecht, J. Randolph, Jean‐Marie Michot, David J. Bajor, et al.. (2025). CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. PubMed. 3(1). 10–10. 1 indexed citations
3.
Elshami, Mohamedraed, Jonathan J. Hue, Richard S. Hoehn, et al.. (2024). Differences in receipt of guideline-compliant care and survival for early-onset versus average-onset biliary tract cancers. 1(1). 100006–100006. 1 indexed citations
4.
Wu, Victoria, David J. Bajor, Sakti Chakrabarti, et al.. (2024). Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Annals of Surgical Oncology. 31(7). 4413–4426. 5 indexed citations
5.
Wu, Victoria, David J. Bajor, Sakti Chakrabarti, et al.. (2024). ASO Visual Abstract: Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Annals of Surgical Oncology. 31(7). 4466–4467. 1 indexed citations
6.
Mohamed, Amr, S. Patil, L. Sylvia, et al.. (2023). The role of somatostatin analogue maintenance therapy in refractory metastatic neuroendocrine tumors (NETs): comparative analysis. Endocrine Abstracts. 1 indexed citations
7.
Elshami, Mohamedraed, Jonathan J. Lee, Jonathan J. Hue, et al.. (2023). Why the Treatment Sequence Matters. Annals of Surgery. 278(4). e677–e684. 6 indexed citations
8.
9.
10.
11.
Biswas, Tithi, et al.. (2020). Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Environmental Research and Public Health. 17(21). 7995–7995. 14 indexed citations
12.
Ocuin, Lee M., Jeffrey M. Hardacre, John B. Ammori, et al.. (2020). Neoadjuvant chemotherapy is associated with improved survival in patients with left‐sided pancreatic adenocarcinoma. Journal of Surgical Oncology. 122(8). 1595–1603. 7 indexed citations
13.
Miller, Tyler E., Michael Yang, David J. Bajor, et al.. (2018). Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. Journal of Clinical Pathology. 71(12). 1108–1115. 34 indexed citations
14.
Lo, Albert, Liang‐Chuan S. Wang, John Scholler, et al.. (2015). Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Research. 75(14). 2800–2810. 407 indexed citations breakdown →
15.
Fu, Ping, Willem J. van Heeckeren, Punit D. Wadhwa, et al.. (2007). Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation. Contemporary Clinical Trials. 29(2). 157–164. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank P. Assen Breakdown of academic impact, for papers by Kellie A. Mouchemore Breakdown of academic impact, for papers by Cody E. Cotner Breakdown of academic impact, for papers by Huda I. Atiya Breakdown of academic impact, for papers by Philippe De La Rochère Breakdown of academic impact, for papers by Matthew A. Lakins Breakdown of academic impact, for papers by Axel Lechner Breakdown of academic impact, for papers by Dorota E. Kuczek Breakdown of academic impact, for papers by Priska Auf der Maur Breakdown of academic impact, for papers by Wilson Wu
Rankless by CCL
2026